Leadership changes afoot at two CGT biotechs
Cell therapy specialist Legend Biotech has announced the abrupt departure of its CEO, while Sarepta has revealed its new leader …
Post
-
-
Apnimed scouts $160m IPO to back late-stage sleep apnoea pill development
Apnimed is eyeing a spot on the Nasdaq exchange through an IPO worth up to $160m, which will support the …
-
BioMarin and n-Lorem partner on early research for ReNU syndrome therapy
BioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global licence agreement to develop an investigational …
-
Argenx signs agreement to buy Forte Biosciences for $2.2bn
argenx has entered a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value. Approved by both companies’ …
-
Why the India-UK trade deal now needs a five-gate implementation ledger
Varun Sharma, founder and CEO of NEUVIOR, reflects on the necessitates of the recently forged India-UK pharma trade deal. Varun Sharma, …
-
Magazine: Made in the USA
A combination of US government incentives, supply chain disruptions, and geopolitical tensions are prompting increased investment in US manufacturing. In …
-
Outlook Therapeutics wins FDA approval for Lytenava in wet AMD
Following years of regulatory setbacks that saw multiple rejections, Outlook Therapeutics has secured US Food and Drug Administration (FDA) approval …
-
Biointron introduces RushData platform for AI-driven antibody discovery
Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies …
-
Kenvue’s Tylenol with Naproxen gains FDA approval
The US Food and Drug Administration (FDA) has approved Kenvue’s Tylenol with Naproxen, the first over-the-counter (OTC) fixed-dose combination of acetaminophen …
-
Adult epilepsy market to reach $17.bn across 7MM by 2035
The adult epilepsy market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) …
-
Sanofi abandons eczema drug approval efforts in another blow to OX40 class
Sanofi has chosen not to file for approval or continue the development of its immunology therapy, amlitelimab, in atopic dermatitis …
-
BeOne to invest $300m in US manufacturing facility expansion
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus …
-
FDA grants fast track designation for Lundbeck’s Lu AH69593
Lundbeck has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational treatment, Lu AH69593, …
-
GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet
Just days after completing a $10.6bn takeover of lung cancer biotech Nuvalent, GSK is already reaping the rewards with Jideytro …
-
Affinia Therapeutics receives FDA orphan drug designation for AFTX-201
Affinia Therapeutics has received the US Food and Drug Administration (FDA) orphan drug designation for AFTX-201, a treatment in development …
